AI illustration · not actual product photoDetails from the source.
Source-listed NAD+ (SKU NJ100): 100mg*10vials. PriceList(1).pdf lists 36 per 10 vials but does not specify currency; the website displays $36 per 10 vials in USD per owner instruction. The source row does not establish the supplier-specific item's identity, lot quality, or approval.
- Catalogue code
- NJ100
- Source specification
- 100mg*10vials
- Source document
- PriceList(1).pdf, page 4
- Photograph
- AI-generated illustration only — not an actual product photo or verified molecular depiction; owner-approved product photo still pending.
Product information is presented from supplied source materials. Inclusion on this website does not state that a product is an approved medicine or authorize human use. This is educational content, not medical advice.
Compound-level research and safety context.
Evidence below concerns the research family associated with this listing. For blends, findings about individual components do not establish evidence for the combination. This does not verify the supplier-specific vial or lot. Reviewed 2026-10-30.
What it is
NAD+ is nicotinamide adenine dinucleotide, a cellular coenzyme and not a peptide. Exact catalogue variants from PriceList(1).pdf: NJ100 — *10vials — 36 per 10 vials; NJ500 — *10vials — 56 per 10 vials; NJ1000 — *10vials — 101 per 10 vials. Currency is not stated in the supplied PDF. Exact source product name remains NAD+; product identity and formulation of the vials are unverified.
Biological mechanism
NAD+ is a redox coenzyme that reversibly accepts/transfers electrons as NADH in cellular energy metabolism. It also serves as a cofactor or substrate for enzymes such as sirtuins, PARPs and CD38, involved in cellular signaling, protein regulation and DNA-damage responses. These biochemical roles do not establish a health benefit from a listed vial.
Research focus
Research examines cellular NAD metabolism and whether NAD availability affects energy metabolism, DNA repair, signaling and age-associated biology. Human research has included direct NAD+ infusion metabolite measurements and studies of NADH or NAD precursors. Most proposed disease-related effects derive from preclinical research or remain clinically unconfirmed.
Potential applications in the evidence
Investigated research areas include NAD metabolism in energy production, aging-associated biology, and metabolic or neurologic settings. These are areas of investigation, not established applications of the catalogue vials. Human findings involving NADH or NAD precursors cannot be treated as evidence for direct NAD+ or this product.
Human evidence
A small controlled pilot studied one supervised intravenous NAD+ infusion in 11 healthy men (8 NAD+, 3 saline) and measured blood and urine metabolites over several hours, not therapeutic efficacy or long-term safety. No adverse events were observed during the short infusion, but the small sample and brief follow-up cannot rule out uncommon or delayed harms. A systematic review of 10 randomized studies with 489 participants included NADH and NAD precursors as well as NAD; it does not establish efficacy for these supplier-specific vials or for injectable NAD+.
Known and potential effects
FDA has received reports of severe chills, shaking, vomiting and fatigue after some NAD+ injectable drugs, with some cases requiring medical treatment. FDA says these reactions are consistent with excessive endotoxin levels. A systematic review of NAD-related supplementation reported muscle pain, nervous-system symptoms, fatigue, sleep disturbance and headache; its evidence includes NADH/precursor studies and cannot be assigned directly to these vials. The small direct-infusion pilot observed no adverse events during its short observation period.
Safety and contraindications
FDA warns that food-grade NAD+ is not suitable for sterile compounding without appropriate processing because of microbial and endotoxin contamination risks. This is a reported quality hazard involving some injectable products, not evidence that these particular SKUs are contaminated. The source catalogue provides no formulation, route, manufacturer, lot-specific quality data or safety documentation. No item-specific contraindications or interaction profile can be verified; safety of the exact item cannot be assessed from the supplied information.
U.S. FDA / regulatory status
FDA has warned about ingredient suitability and adverse events involving some NAD+ injectable drugs. FDA states that compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality before marketing; however, the supplied catalogue does not establish that these items are compounded. No manufacturer, lot, formulation source, jurisdiction or approval number is provided, so FDA approval for NJ100, NJ500 or NJ1000 cannot be verified. Do not imply that status of NAD, NAD precursors, or another branded formulation transfers to these supplier-specific vials.
Evidence limitations
Direct human evidence for NAD+ infusion is sparse and limited to a small, short-term metabolite study. NADH and precursor studies are not interchangeable with direct NAD+ or the listed vials. Preclinical findings do not establish human benefit. Product identity, composition, manufacturing quality, sterility, endotoxin levels, regulatory status and equivalence to studied materials cannot be verified from the catalogue.
Supporting sources
- FDA reminds compounders to use ingredients suitable for sterile compounding U.S. Food and Drug Administration · FDA safety communication. Supports: FDA's warning about food-grade NAD+ ingredients, microbial/endotoxin risks, and reported severe chills, shaking, vomiting and fatigue after some NAD+ injectable drugs.
- A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD Frontiers in Aging Neuroscience; PubMed Central · Primary human pilot study. Supports: Small controlled human infusion metabolite study, its short-term safety observations, study population and limits; does not establish clinical efficacy or product equivalence.
- Evaluation of safety and effectiveness of NAD in different clinical conditions: a systematic review American Journal of Physiology-Endocrinology and Metabolism; PubMed · Systematic review of randomized clinical studies. Supports: Scope and limitations of human clinical evidence across NAD/NADH/precursor studies and reported adverse effects; not evidence for the exact vials.
- NAD+ metabolism and its roles in cellular processes during ageing Nature Reviews Molecular Cell Biology; PubMed Central · Peer-reviewed review. Supports: NAD+ redox cofactor functions, NADH conversion, NAD-dependent enzymes and distinction between extensive preclinical research and less advanced human evidence.
- Compounding and the FDA: Questions and Answers U.S. Food and Drug Administration · FDA regulatory information. Supports: FDA's explanation that compounded drugs are not FDA-approved and are not FDA-reviewed for safety, effectiveness or quality before marketing; the source does not establish that this catalogue item is compounded.